| Identification | Back Directory | [Name]
4-Morpholinepropanamide, N-[5-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-3-[(ethylamino)carbonyl]-4-isoxazolyl]-, hydrochloride (1:1) | [CAS]
1799802-29-1 | [Synonyms]
4-Morpholinepropanamide, N-[5-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-3-[(ethylamino)carbonyl]-4-isoxazolyl]-, hydrochloride (1:1) | [Molecular Formula]
C22H30N4O6.ClH | [MOL File]
1799802-29-1.mol | [Molecular Weight]
482.96 |
| Hazard Information | Back Directory | [Uses]
SST0116CL1 is a HSP90 inhibitor (IC50: 0.21 μM). SST0116CL1 binds to the ATP binding pocket of Hsp90, and interferes with Hsp90 chaperone function thus resulting in client protein (EGFR, CDK4 and AKT) degradation. SST0116CL1 induces degradation of Her2 in BT-474 cell (IC50: 0.2 μM). SST0116CL1 has antiproliferative activity and inhibits tumor growth[1]. | [References]
[1] Vesci L, et al. Preclinical antitumor activity of SST0116CL1: a novel heat shock protein 90 inhibitor. Int J Oncol. 2014 Oct;45(4):1421-9. DOI:10.3892/ijo.2014.2575 |
|
|